In its recent newsletter, FAST published an interview with Annemieke Aartsma-Rus and Willeke van Roon-Mom about DCRT's efforts to develop tailored treatment with AONs for patients with a unique genetic disease. Dr Jasper Claessen from the Ministry of Health, Welfare and Sport welcomes this academic initiative but at the same time realizes that issues such as measurement of effectiveness and safety of the drug and the costs of personalized treatment must be addressed first.
posted on December 5, 2024
Let us know your questions or suggestions.